Varda ships cancer drug to orbit after $251M raise to test space-made crystals
What's the deal? Varda Space Industries launched its W-7 capsule on October 20, 2026, to test whether microgravity can improve a promising class of cancer drugs known as PROTACs. The spacecraft lifted off from Cape Canaveral, Florida, on a SpaceX Falcon 9 multi-payload mission.
What's the endgame? PROTACs tag disease-causing proteins for destruction rather than merely blocking them, but the large molecules are often hard to formulate because they dissolve poorly in the body. In microgravity, molecules can crystallise differently, potentially yielding crystal forms with better solubility.
Why now? W-7 is Varda's third launch this month. Its W-8 and W-9 capsules flew together earlier in October, and the company closed a $251 million Series D on September 30, 2026, to scale space-based pharmaceutical processing.
"The most sophisticated molecule in the world doesn't help a patient if it can't be absorbed by the body," said Michael Reilly, chief strategy officer at Varda. "With W-7, we're testing unique physics of microgravity in pursuit of solving a formulation problem that limits an entire class of cancer drugs."
What could go wrong? W-7 is a research test, not a drug launch. The capsule will return PROTAC crystals to Earth for analysis, and any solubility advantage remains unproven. Varda has demonstrated a return-and-analysis workflow before, including earlier work on ritonavir crystals, but that does not establish that space-grown formulations will be clinically useful or economical at scale.
Beyond pharmaceuticals, Varda also offers hypersonic testing and re-entry services. Chief strategy officer Michael Reilly said the company plans a clinical effort around a United Therapeutics treatment in 2027.
The signal: Varda is betting that routine access to low Earth orbit can turn drug manufacturing into a practical business. W-7 tests whether that process can solve a specific formulation problem — and the result that matters is the measured properties of the returned crystals, not the launch itself.
Read more: Axios, PR Newswire
Image credit: SpaceX, CC0, via Wikimedia Commons
